JOHN FOREYT to Anti-Obesity Agents
This is a "connection" page, showing publications JOHN FOREYT has written about Anti-Obesity Agents.
Connection Strength
1.995
-
Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. Clin Obes. 2016 Oct; 6(5):305-12.
Score: 0.524
-
Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat. J Intern Med. 2006 Oct; 260(4):388-98.
Score: 0.265
-
Does metabolic syndrome mitigate weight loss in overweight Mexican American women treated for 1-year with orlistat and lifestyle modification? Eat Weight Disord. 2006 Mar; 11(1):e35-41.
Score: 0.255
-
Behavioral interventions for obesity. J Am Diet Assoc. 2005 May; 105(5 Suppl 1):S35-43.
Score: 0.240
-
Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. Int J Obes Relat Metab Disord. 2003 Dec; 27(12):1486-93.
Score: 0.218
-
Lifestyle treatments in randomized clinical trials of pharmacotherapies for obesity. Obes Res. 2001 Sep; 9(9):552-63.
Score: 0.186
-
Scientific and legal issues in fenfluramine/dexfenfluramine litigation. Tex Med. 2000 Feb; 96(2):48-56.
Score: 0.167
-
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002 Jul; 25(7):1123-8.
Score: 0.049
-
Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002 Feb; 26(2):262-73.
Score: 0.048
-
Successful management of the obese patient. Am Fam Physician. 2000 Jun 15; 61(12):3615-22.
Score: 0.043